A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.

View in: PubMed

subject areas

Administration, Intravenous
Administration, Intravenous
Aged
Aged
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Cisplatin
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Doxorubicin
Doxorubicin
Endometrial Neoplasms
Endometrial Neoplasms
Female
Female
Humans
Humans
Infusions, Parenteral
Infusions, Parenteral
Middle Aged
Middle Aged
Neoplasm Staging
Neoplasm Staging
Paclitaxel
Paclitaxel

authors with profiles

Joan L Walker